YUM70
Based on 4 publication(s) in Google Scholar
YUM70 is a potent and selective inhibitor of glucose-regulated protein 78 (GRP78), with an IC50 of 1.5 μM for inhibiting GRP78 ATPase activity of the full-length protein. YUM70 induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer. YUM70 also has in vivo efficacy in a pancreatic cancer xenograft model.
For research use only. We do not sell to patients.
- Purity : 98.01%
- CAS No.: 423145-35-1
- Formula: C21H19ClN2O4
- Molecular Weight:398.84
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-100437
HA15BiP/GRP78/HSPA5 Inhibitor -
HY-10214
SNX-2112 -
HY-14463
OnalespibHsp90 Inhibitor -
HY-10941
VER-155008Hsp70 Inhibitor -
HY-10211
TanespimycinHSP90 Inhibitor -
HY-15205
GanetespibHSP90 Inhibitor -
HY-110188
BiP inducer XBiP/GRP78 Inducer -
HY-10213
SNX-5422 -
HY-10212
BIIB021HSP90 Inhibitor -
HY-10215
LuminespibHSP90 Inhibitor -
HY-13469
Debio 0932HSP90 Inhibitor -
HY-Y0873
PEG300Neutral Polymer
Publications Citing Use of MedChemExpress (MCE) YUM70
More
Biological Activity
Description
IC50 & Target
|
Grp78 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 37690265] |
| BXPC-3 | IC50 |
9.6 μM
Compound: 21; YUM70
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell proliferation incubated for 4 hrs by MTS assay
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell proliferation incubated for 4 hrs by MTS assay
|
[PMID: 37690265] |
| MCF7 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37690265] |
| MIA PaCa-2 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 37690265] |
| NCI-H1299 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 37690265] |
| OVCAR-3 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37690265] |
| OVCAR-8 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human OVCAR-8 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human OVCAR-8 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37690265] |
| PANC-1 | IC50 |
4.5 μM
Compound: 21; YUM70
|
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 37690265] |
| SH-SY5Y | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human SH-SY5Y cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human SH-SY5Y cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37690265] |
| SK-OV-3 | IC50 |
2.8 μM
Compound: 21; YUM70
|
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37690265] |
In Vitro
YUM70 shows selective cytotoxicity for MIA PaCa-2, PANC-1, BxPC-3 cells (IC50=2.8, 4.5, and 9.6 μM, respectively) over normal pancreatic tissue-derived HPNE cells (IC50>30 μM)[1].
YUM70 (5 μM; 24 h) induces endoplasmic reticulum (ER) stress-mediated apoptosis of MIA PaCa-2cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MIA PaCa-2, PANC-1 cells
-
Concentration:0.1, 1, 2.5, 5, 10 μM
-
Incubation Time:2, 4, 8, 24, 48 hours
-
Result:Increased the protein levels of FAM129A, DDIT3, CHAC-1, DDIT4, UPP1, and GRP78 in a dose- and time-dependent manner.
In Vivo
YUM70 (15 mg/kg; i.v.) exhibits t1/2 (1.40 h), CL (724.04 mL/h/kg), and Vss (1162.73 mL/kg) in mice[1].
YUM70 (30 mg/kg; p.o.) exhibits bioavailability (6.71%), t1/2 (2.74 h), and CL (9230.15 mL/h/kg) in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8-week old female NCr nude mice were injected with MIA PaCa-2 cells[1]
-
Dosage:30 mg/kg
-
Administration:I.p. 5 days a week for 7 weeks
-
Result:Observed a significant tumor growth delay with no significant change in body weight during the course of treatment.
Chemical Information
-
CAS No. 423145-35-1
-
Appearance Solid
-
Molecular Weight 398.84
-
Formula C21H19ClN2O4
-
Color White to off-white
-
SMILES
CCCC(NC(C1=CC=C(OCO2)C2=C1)C3=CC(Cl)=C4C=CC=NC4=C3O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Mol Biomed
Death-associated protein kinase 2 (DAPK2) propagates endoplasmic reticulum stress in macrophages to worsen sepsis through HSPA5-IRE1α axis. [Abstract]2026 Jun 23;7(1):94. PMID: 42334722 -
EMBO Mol Med
NRF3 suppresses squamous carcinogenesis, involving the unfolded protein response regulator HSPA5. [Abstract]2023 Nov 8;15(11):e17761. PMID: 37807968 -
Mol Cancer Ther
Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma. [Abstract]2026 Feb 11. PMID: 41670299 -
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (250.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.27 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5073 mL | 12.5364 mL | 25.0727 mL | 62.6818 mL |
| 5 mM | 0.5015 mL | 2.5073 mL | 5.0145 mL | 12.5364 mL | |
| 10 mM | 0.2507 mL | 1.2536 mL | 2.5073 mL | 6.2682 mL | |
| 15 mM | 0.1672 mL | 0.8358 mL | 1.6715 mL | 4.1788 mL | |
| 20 mM | 0.1254 mL | 0.6268 mL | 1.2536 mL | 3.1341 mL | |
| 25 mM | 0.1003 mL | 0.5015 mL | 1.0029 mL | 2.5073 mL | |
| 30 mM | 0.0836 mL | 0.4179 mL | 0.8358 mL | 2.0894 mL | |
| 40 mM | 0.0627 mL | 0.3134 mL | 0.6268 mL | 1.5670 mL | |
| 50 mM | 0.0501 mL | 0.2507 mL | 0.5015 mL | 1.2536 mL | |
| 60 mM | 0.0418 mL | 0.2089 mL | 0.4179 mL | 1.0447 mL | |
| 80 mM | 0.0313 mL | 0.1567 mL | 0.3134 mL | 0.7835 mL | |
| 100 mM | 0.0251 mL | 0.1254 mL | 0.2507 mL | 0.6268 mL |
YUM70 Related Classifications
HY-138364 Related Classifications
Powered by Bioz